Engage Bio is a biotechnology company pioneering the development of Tethosomes, a novel class of non-viral DNA medicines designed to overcome the traditional challenges of potency and toxicity in genetic therapies. By utilizing lipid nanoparticle (LNP) technology, Engage Bio delivers therapeutic DNA alongside mRNA encoding their proprietary Tethosome protein. This protein facilitates the localization of DNA to the nucleus, enhancing gene expression by over 100-fold. Importantly, the Tethosome platform is engineered to evade immune detection, allowing for safe administration, the possibility of re-dosing, and the ability to adjust expression levels to achieve optimal therapeutic outcomes. Key Features and Functionality: - High Potency: Achieves gene expression levels exceeding 100 times that of conventional non-viral DNA methods. - Non-Immunogenic: Designed to be invisible to immune sensors that typically detect foreign DNA, reducing the risk of adverse immune reactions. - Redosable: Provides sustained gene expression from a single dose, with the capability for safe re-dosing as needed. - Scalable Manufacturing: Employs low-complexity manufacturing processes using established LNP technology, facilitating scalability. Primary Value and User Solutions: Engage Bio's Tethosome platform addresses critical limitations in the field of genetic medicine by enhancing the efficacy and safety of DNA-based therapies. By significantly increasing gene expression while minimizing immune responses, Tethosomes enable the development of potent, durable, and re-dosable treatments. This innovation holds promise for a wide range of applications, including gene replacement therapies, oncology treatments, and the expression of therapeutic proteins, ultimately aiming to improve patient outcomes and expand the possibilities within genetic medicine.